Orthovisc products are sodium hyaluronate injections developed by Anika Therapeutics, a multi-national medicine technology company headquartered in Massachusetts, United States. The company specializes in the development of hyaluronic acid (HA) therapeutic products, offering innovative pain management solutions for patients who suffer from degenerative orthopedic diseases. Orthovisc has been approved by the Food and Drug Administration (FDA) since February 2004.
Orthovisc hyaluronic acid injections can offer long-lasting results. In most cases, the results can last up to 26 weeks, or approximately 6 months. Please note that individual results may vary depending on a range of patient-related factors.
Orthovisc products are generally safe and not likely to cause severe adverse effects. They are contraindicated in individuals with a known allergy to any of the ingredient in the products, infection of the index joint, systemic bleeding disorders, or pre-existing skin infections in the region of the intended injection site.
This may not be all of the contraindications for Orthovisc products, as some of the products may have different contraindications from others from the brand. For more information on a product’s contraindications, refer to the package insert.
Some of the potential side effects associated with Orthovisc include but are not limited to the following:
Orthovisc products are administered via a minimally invasive method that is associated with minimal recovery time.
Orthovisc products range in price from $45.00 USD to $52.00 USD.